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preterm stop of the therapy thus jeopardizing the intended 
treatment outcome. Despite numerous research attempts 
there is still no robust feature established in clinical routine 
to predict radiotherapy-induced toxicity prior to therapy 
start. 
 
Material and Methods: The study cohort comprised 40 
patients who underwent neoadjuvant radiochemotherapy (N-
RCT) for rectal cancer (28x1.8 Gy, 5 times weekly, 
concomitant with two cycles 5-FU-based chemotherapy). 
From each of those patients dermal fibroblasts were cultured 
from skin specimen gained outside of the radiotherapy 
planning target volume at occasion of surgery conducted 
about six weeks upon N-RCT completion. Acute radiotoxicity 
was thoroughly monitored throughout the N-RCT series and 
documented according to CTC classification. Maximal acute 
toxicity (MAT) was defined by the highest CTC grade of the 
four items “cystitis”, “proctitis”, “enteritis”, and 
“dermatitis”. MAT was grouped into grades 0/1 (n=16), 2 
(n=16), and 3/4 (n=8). N-RCT was simulated in the cultured 
fibroblasts for five consecutive days (1.8 Gy each at d1-d5 
with addiation of 5-FU at a concentration reflecting clinical 
steady-state levels) followed by a 7-day wash-out period. 
Gene expression of nine candidate genes (CAT, CDKN1A, 
CTGF, SMAD2/3/4/7, TGFB1, TGFBR1) supposed to mediate 
early radiation-induced toxicity was ascertained by 
quantitative real time PCR. Samples for these RNA analyses 
were harvested at d2 and d5 (each 4 hours upon application 
of the radiation fraction) as well as at day 12 upon the wash-
out period. GAPDH and HPRT1 transcript levels served as 
reference. 
 
Results: MAT was related to radiation-induced expression 
changes of four of the considered genes in fibroblasts. The 
strongest impact was obtained for SMAD7 and CAT at d5. The 
higher the MAT score, the lower the induction of SMAD7 and 
CAT by radiation was (p=0.001 and 0.003). However, upon 
the wash-out period at d12 no statistical differences in 
dependence on the MAT score were seen anymore for these 
two genes. In contrast, a high MAT score was linked to low 
radiation-induced induction of CTGF (p=0.005) and to a faster 
decrease of the massively induced CDKN1A (p=0.03) at d12. 
At d2, a trend (p=0.06) for CAT in relation to MAT in the 
same direction as at d5 was noticed with no correlation of 
any of the other genes at this early time point. 
 
Conclusion: Radiation-induced expression changes in patient-
matched fibroblasts may serve as biomarkers to predict 
clinical radiotoxicity. Induction of SMAD7 and CAT may 
mitigate TGFbeta signalling and reactive oxygen species load 
thus saving normal tissue during radiotherapy. A protective 
role might also be attributed to sustained elevation of 
CDKN1A. The link between post-radiation induction of CTGF 
in fibroblasts and low MAT remains to be clarified. 
Understanding the mechanistic basis of these findings might 
pave the way for better protection of irradiated normal 
tissue. 
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Purpose or Objective: Erectile dysfunction (ED) is one of the 
most common complications encountered after radiotherapy 
in prostate cancer patients. The goal of this study was to 
investigate whether single nucleotide polymorphisms (SNPs) 
are associated with late ED in men treated with radiotherapy 
for prostate cancer. To this end, we designed a novel 
machine learning-based multi-SNP model using a genome-
wide association study (GWAS) dataset. 
 
Material and Methods: We analyzed 236 evaluable patients 
with at least one year of follow-up for the development of 
ED. The severity of ED was assessed using either the patient-
administered Sexual Health Inventory for Men (SHIM) or the 
clinician-assigned Mount Sinai Erectile Function (MSEF) 
scoring schema. There were 133 patients with Grade 2 or 
more ED. For our analysis, the cohort was split into two 
groups (cases/controls: MSEF 0,1 / 2,3; cases/controls: SHIM 
≤7 / ≥16). Genome-wide SNP data were available from 
Affymetrix Genome-Wide Human SNP Array 6.0. After a 
quality test including SNP missing rate>5%, minor allele 
frequency (MAF)<5%, and Hardy-Weinberg equilibrium 
(p<10E-5), 613,496 SNPs remained. 
For the validation purpose of our proposed model, the 
dataset was split into a training dataset (2/3 of samples) and 
a validation dataset (1/3 of samples). Our model building 
process was performed using the bootstrapped data from the 
training dataset. Our idea is to convert the binary outcomes 
into preconditioned continuous outcomes based on normal 
tissue complication probability (NTCP) using principal 
component analysis (PCA) and logistic regression. The 
preconditioned outcomes were used in the model building 
process using random forest regression. Then, the model was 
tested using the validation dataset. The final predicted 
outcomes were compared with the original binary outcomes 
to estimate the predictive performance. We iterated this 
process 100 times and the performance was averaged. We 
compared the performance of our proposed method 
(preconditioning random forest regression: PRFR) with other 
methods including preconditioning lasso (PL), lasso logistic 
regression (LLR), and random forest classification (RFC). 
 
Results: Univariate analysis was performed using the training 
dataset. With a threshold of p=0.001, 367 SNPs remained. 
These SNPs were fed into our model. As shown in Figure (A), 
the averaged performance with the validation dataset was 
AUC=0.62, which is better than other methods: RFC (0.57), 
PL (0.58), and LLR (0.57). The 79 patients in the validation 
dataset were binned into 6 groups according to the predicted 
risk of ED. Figure (B) shows the comparison of the model-
predicted incidence of ED with observed incidence.  
 
Conclusion: Our machine learning-based multi-SNP model 
showed the potential to better predict the radiation-induced 
late ED. However, we need to validate our model using other 
datasets. 
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Purpose or Objective: Tumor hypoxia, a common feature of 
locally advanced head and neck cancer (HNSCC), is 
associated with higher malignancy and increased 
radioresistance. The decrease of tumor hypoxia during 
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fractionated radiation treatment is assumed to be decisive 
for treatment success. [18F]-Fluoro-Misonidazole PET (F-
MISO-PET) allows noninvasive assessment of hypoxia during 
treatment. The purpose of the present study was to 
noninvasively assess the time course of tumor hypoxia. 
 
Material and Methods: A prospective serial imaging study 
was conducted in patients undergoing definitive 
chemoradiation (dRCTx, total dose 70Gy) for locally 
advanced HNSCC, accompanied by cisplatin in weeks 1, 4 and 
7. Tumor hypoxia was assessed by F-MISO-PET by static scans 
acquired 2.5 h p.i. Tumor volumes were determined for FDG 
PET/CT scans and the coregistered F-MISO/CT scans. At 
baseline MRI, FDG-PET/CT and F-MISO-PET were acquired 
(week 0). Additional F-MISO-PET/CT scans were acquired in 
treatment weeks 2 and 5. Normal sample distribution was 
confirmed with Shapiro-Wilk test. Unpaired t-test analysis of 
the mean SUVmax(tumor)/SUVmean(muscle) ratios of F-MISO-
PET in weeks 0, 2 and 5 were performed. Significance-level 
was defined as p<0.005. 
 
Results: Between 2012 and 2014 18 patients (16 men, two 
women, mean age 60 years), treated for HNSCC with dRCTx 
were included. All received a total dose of 70 Gy in 35 
fractions. Concomitant cisplatin chemotherapy was 
administered in weeks 1, 4 and 7. 14 patients had all F-MISO-
PET scans, while 4 had two F-MISO-PET scans (week 0, 5). 
The mean follow-up time was 14.6 months (range: 4 - 28 
months). Mean SUVmax(tumor)/SUVmean(muscle) in weeks 0, 
2 and 5 were 1.9 (n=18, SD ± 0.1), 1.5 (n=14, SD ± 0.1) and 
1.2 (n=18, SD ± 0.1), respectively. Unpaired t-test for 
SUVmax(tumor)/SUVmean(muscle) between week 0 and 5 
was performed, showing a singnificant decrease (p<0.0001). 
Between weeks 0 and 2 (p=0.0346) and between weeks 2 and 
5 the decrease again was highly significant (p=0.0113). In two 
patients no residual hypoxia was measured in week two, 
resulting in SUVmax(tumor)/SUVmean(muscle) =1.0. In week 
5 this was found in seven patients. In two patients hypoxia 
had increased in week 2 but decreased in week 5 compared 
to pre-treatment measurements. In one patient hypoxia had 
increased by the end of treatment.  
 
 
Conclusion: Differences in hypoxia between weeks 0-2, 2-5 
and 0- 5, respectively, show statistical significance. This is 
crucial in the process of re-oxygenation. As concluded in 
previous works, change of treatment strategy, e.g. by means 
of dose escalation might be most efficient early during 
treatment. However further analysis, with more patients and 
correlation to disease-free and overall-survival are needed. 
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Purpose or Objective: There is increasing interest in 
maximising data extraction from the multimodality imaging 
performed in cancer patients in order to predict treatment 
outcomes. This is particularly relevant in Oropharyngeal 
cancer where concomitant chemoradiotherapy is the 
standard treatment in stage III and IV disease but there is 
significant variation in patient outcomes and both treatment 
intensification and de-intensification strategies are being 
investigated.  
The aim of this prospective pilot study was to look at how 
data obtained from pre- and per-treatment 18F-FDG-PET/CT 
scans and textural features from pre- and per-treatment 
contrast enhanced planning CT scans correlated with known 
prognostic indicators including smoking history and HPV 
status.  
 
Material and Methods: Eligible patients included those 
undergoing primary concomitant chemoradiotherapy for 
Stage III/IV SCC of the Oropharynx. Each patient underwent a 
contrast enhanced planning CT and an 18F-FDG-PET/CT scan 
immobilised in the treatment position prior to the start of 
treatment and then again after 8-10 fractions of 
radiotherapy. The SUVmax and SUVmean were recorded on 
both the pre- and per- treatment 18F-FDG-PET/CT. Texture 
analysis was performed using TexRad software on both the 
pre- and per-treatment planning CT scans. The smoking 
history for each patient was established on enrolment to the 
study and HPV status was determined using p16 IHC on biopsy 
of the primary tumour. Ethical approval was gained from the 
relevant bodies. 
 
Results: Eighteen patients were recruited. HPV status was 
positive in 13 patients and negative in 5 patients. The 
SUVmax/mean in HPV negative patients was 21.6/13.3 on the 
pre-treatment 18F-FDG-PET/CT versus 15.2/10.5 for HPV 
positive patients (p= 0.09/0.25). Pre-treatment CT texture 
analysis showed a difference in the normalised entropy 
between the two groups with a significant difference 
detected using the smallest filter (p=0.04). The 
SUVmax/mean on the pre-treatment 18F-FDG-PET/CT for 
patients with no or minimal smoking history (<10 years) was 
13.7/9.5 versus 19.1/12.9 for those with a smoking history of 
>10years (p= 0.1/0.13). No significant difference in the 
entropy/entropy ratio between the two groups was detected. 
No significant differences were shown in the change in SUV or 
entropy ratio between the pre-and per-treatment scans in 
any of the groups. 
 
Conclusion: These results suggest differences in the imaging 
characteristics between patients in different prognostic 
categories may be detected at the pre-treatment stage and 
are worthy of further investigation in a larger patient cohort 
and may in the future add further information to that 
provided by the molecular profiling of tumours. This study 
did not show any significant differences in the data obtained 
between patients in terms of their early response to 
treatment however this data can be revisited once follow up 
data for this patient cohort matures. 
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Purpose or Objective: This study looking for the prognosis 
value of over-expression of EGFR and/or COX-2 in patients 
with locally advanced squamous cervical carcinoma (LASC). 
 
